Oncosem Onkolojik Sistemler Sanayi ve Ticaret A.S.
Oncosem Onkolojik Sistemler Sanayi Ve Ticaret Anonim Sirketi manufactures and sells chemotherapy drug preparation kits, medical devices, and test kits in Turkey. The company offers OncoCare Monolitik, an automated chemotherapy drug preparation device; OncoCare Plus, a chemotherapy drug guide; OncoWaste and M-Waste, a hazardous waste sealing system, chemotherapy drugs, cephalosporins, penicillins,… Read more
Oncosem Onkolojik Sistemler Sanayi ve Ticaret A.S. (ONCSM) - Total Assets
Latest total assets as of September 2024: TL384.37 Million TRY
Based on the latest financial reports, Oncosem Onkolojik Sistemler Sanayi ve Ticaret A.S. (ONCSM) holds total assets worth TL384.37 Million TRY as of September 2024.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Oncosem Onkolojik Sistemler Sanayi ve Ticaret A.S. - Total Assets Trend (2020–2023)
This chart illustrates how Oncosem Onkolojik Sistemler Sanayi ve Ticaret A.S.’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Oncosem Onkolojik Sistemler Sanayi ve Ticaret A.S. - Asset Composition Analysis
Current Asset Composition (December 2023)
Oncosem Onkolojik Sistemler Sanayi ve Ticaret A.S.'s total assets of TL384.37 Million consist of 57.7% current assets and 42.3% non-current assets.
| Asset Category | Amount (TRY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | TL0.00 | 17.3% |
| Accounts Receivable | TL54.41 Million | 16.1% |
| Inventory | TL77.64 Million | 23.0% |
| Property, Plant & Equipment | TL0.00 | 0.0% |
| Intangible Assets | TL4.85 Million | 1.4% |
| Goodwill | TL0.00 | 0.0% |
Asset Composition Trend (2020–2023)
This chart illustrates how Oncosem Onkolojik Sistemler Sanayi ve Ticaret A.S.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Oncosem Onkolojik Sistemler Sanayi ve Ticaret A.S.'s current assets represent 57.7% of total assets in 2023, an increase from 31.7% in 2020.
- Cash Position: Cash and equivalents constituted 17.3% of total assets in 2023, up from 6.4% in 2020.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 1.0% of total assets, an increase from 0.0% in 2020.
- Asset Diversification: The largest asset category is inventory at 23.0% of total assets.
Oncosem Onkolojik Sistemler Sanayi ve Ticaret A.S. Competitors by Total Assets
Key competitors of Oncosem Onkolojik Sistemler Sanayi ve Ticaret A.S. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Shanghai Kehua Bio-Engineering Co Ltd
SHE:002022
|
China | CN¥5.17 Billion |
|
Jiangsu Yuyue Medical Equipment & Supply Co Ltd
SHE:002223
|
China | CN¥16.67 Billion |
|
Double Medical Technology Inc
SHE:002901
|
China | CN¥4.55 Billion |
|
Wuhan Easy Diagnosis Biomedicine Co Ltd Class A
SHE:002932
|
China | CN¥6.10 Billion |
|
Shinhung
KO:004080
|
Korea | ₩153.50 Billion |
|
UMediC Group Berhad
KLSE:0256
|
Malaysia | RM94.93 Million |
|
Osang Healthcare Co.,Ltd
KQ:036220
|
Korea | ₩287.70 Billion |
|
HansBiomed Corporation
KQ:042520
|
Korea | ₩126.41 Billion |
Oncosem Onkolojik Sistemler Sanayi ve Ticaret A.S. - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Strong asset utilization - Oncosem Onkolojik Sistemler Sanayi ve Ticaret A.S. generates 0.71x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Oncosem Onkolojik Sistemler Sanayi ve Ticaret A.S. is currently not profitable relative to its asset base.
Oncosem Onkolojik Sistemler Sanayi ve Ticaret A.S. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.15 | 2.84 | 2.84 |
| Quick Ratio | 1.42 | 2.02 | 2.02 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | TL118.21 Million | TL 117.53 Million | TL 117.53 Million |
Oncosem Onkolojik Sistemler Sanayi ve Ticaret A.S. - Advanced Valuation Insights
This section examines the relationship between Oncosem Onkolojik Sistemler Sanayi ve Ticaret A.S.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 15.47 |
| Latest Market Cap to Assets Ratio | 0.09 |
| Asset Growth Rate (YoY) | -3.2% |
| Total Assets | TL338.31 Million |
| Market Capitalization | $30.36 Million USD |
Valuation Analysis
Below Book Valuation: The market values Oncosem Onkolojik Sistemler Sanayi ve Ticaret A.S.'s assets below their book value (0.09 x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: Oncosem Onkolojik Sistemler Sanayi ve Ticaret A.S.'s assets decreased by 3.2% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Oncosem Onkolojik Sistemler Sanayi ve Ticaret A.S. (2020–2023)
The table below shows the annual total assets of Oncosem Onkolojik Sistemler Sanayi ve Ticaret A.S. from 2020 to 2023.
| Year | Total Assets | Change |
|---|---|---|
| 2023-12-31 | TL338.31 Million | -3.22% |
| 2022-12-31 | TL349.58 Million | +169.84% |
| 2021-12-31 | TL129.55 Million | -1.95% |
| 2020-12-31 | TL132.13 Million | -- |